Skip to main content
SpringerLink
Log in

Discovery of G-CSF and Early Clinical Studies

  • Chapter
  • First Online:
Twenty Years of G-CSF

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

In the 1960s, two groups simultaneously developed methods for growing colonies of granulocytes and monocytes from mouse bone marrow or spleen cells in semisolid agar (for review, see [1]). The colony growth was dependent on the presence of unknown factors, which were given the operational name colony-stimulating factors (CSF). Efforts to biologically identify and biochemically purify these CSF kept many laboratories busy until the middle of the 1980s and revealed that there is no single CSF, but rather four quite biochemically different CSF with different colony-stimulating activities. The four CSF were given names dependent on the type of colonies: GM-CSF stimulated granulocyte and macrophage colonies; M-CSF, macrophage colonies; G-CSF, granulocyte colonies; and multi-CSF (interleukin [IL-3]), a broad range of hematopoietic cell colonies [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Metcalf D (2010) The colony-stimulating factors and cancer. Nat Rev Cancer 10:425–434

    Article  PubMed  CAS  Google Scholar 

  2. Nicola NA, Metcalf D, Matsumoto M, Johnson GR (1983) Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. J Biol Chem 258:9017–9023

    PubMed  CAS  Google Scholar 

  3. Welte K, Platzer E, Lu I et al (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 82:1526–1530

    Article  PubMed  CAS  Google Scholar 

  4. Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (1982) Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 156:454–464

    Article  PubMed  CAS  Google Scholar 

  5. Ihle JN, Keller J, Henderson L, Klein F, Palaszynski E (1982) Procedures for the purification of interleukin 3 to homogeneity. J Immunol 129:2431–2436

    PubMed  CAS  Google Scholar 

  6. Souza LM, Boone TC, Gabrilove J et al (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232:61–65

    Article  PubMed  CAS  Google Scholar 

  7. Nomura H, Imazeki I, Oheda M et al (1986) Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J 5:871–876

    PubMed  CAS  Google Scholar 

  8. Nagata S, Tsuchiya M, Asano S et al (1986) Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319:415–418

    Article  PubMed  CAS  Google Scholar 

  9. Fukunaga R, Ishizaka-Ikeda E, Nagata S (1990) Purification and characterization of the receptor for murine granulocyte-colony-stimulating factor. J Biol Chem 265:14008–14015

    PubMed  CAS  Google Scholar 

  10. Skokowa J, Cario G, Uenalan M et al (2006) LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 12:1191–1197

    Article  PubMed  CAS  Google Scholar 

  11. Skokowa LD, Thakur BK et al (2009) NAMPT is essential for the G-CSF induced myeloid differentiation via NAD+-sirtuin-1-dependent pathway. Nat Med 15:151–158

    Article  PubMed  CAS  Google Scholar 

  12. Platzer E, Welte K, Gabrilove JL et al (1985) Biological activities of a human pluripotent hematopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 162:1788–1801

    Article  PubMed  CAS  Google Scholar 

  13. Strife A, Lambek C, Wisniewski D et al (1987) Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood 69:1508–1523

    PubMed  CAS  Google Scholar 

  14. Lieschke GJ, Grail D, Hodgson G et al (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737–1746

    PubMed  CAS  Google Scholar 

  15. Welte K, Bonilla MA, Gillio AP et al (1987) Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 165:941–948

    Article  PubMed  CAS  Google Scholar 

  16. Gillio AP, Bonilla MA, Potter GK et al (1987) Effects of recombinant human granulocyte colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 19:153

    PubMed  CAS  Google Scholar 

  17. Gabrilove JL, Jakubowski A, Scher H et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422

    Article  PubMed  CAS  Google Scholar 

  18. Bronchud MH, Scarfe JH, Thatcher N et al (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809–813

    Article  PubMed  CAS  Google Scholar 

  19. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170

    Article  PubMed  CAS  Google Scholar 

  20. Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324

    Article  PubMed  CAS  Google Scholar 

  21. Lowenberg B, Touw IT (1993) Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281–292

    PubMed  CAS  Google Scholar 

  22. Ohno R, Naoe T, Kanamaru A et al (1994) A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2015–2019

    Google Scholar 

  23. Estey E, Thall P, Andreeff M et al (1994) Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671–678

    PubMed  CAS  Google Scholar 

  24. Giralt S, Escudier S, Kantarjian H et al (1993) Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329:757–761

    Article  PubMed  CAS  Google Scholar 

  25. Welte K, Reiter A, Mempel K et al (1996) A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 87:3143–3150

    PubMed  CAS  Google Scholar 

  26. Taylor KM, Jagganath S, Spitzer G et al (1989) Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin‘s disease. J Clin Oncol 7:1791–1799

    PubMed  CAS  Google Scholar 

  27. Sheridan WP, Morstyn G, Wolf M et al (1989) Granulocyte colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891–895

    Article  PubMed  CAS  Google Scholar 

  28. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074–2081

    PubMed  Google Scholar 

  29. Sheridan WP, Begley CG, Juttner CA et al (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644

    Article  PubMed  CAS  Google Scholar 

  30. De Luca E, Sheridan WP, Watson D, Szer J, Begley CG (1992) Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 66:893–899

    Article  Google Scholar 

  31. Bensinger W, Singer J, Appelbaum F et al (1993) Autologous transplantation with peripheral blood progenitor mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158–3163

    PubMed  CAS  Google Scholar 

  32. Bonilla MA, Gillio AP, Ruggeiro M et al (1989) Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 320:1574–1580

    Article  PubMed  CAS  Google Scholar 

  33. Welte K, Zeidler C, Reiter A et al (1990) Differential effects of granulocyte-macrophage colony stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75:1056–1063

    PubMed  CAS  Google Scholar 

  34. Dale DC, Bonilla MA, Davis MS et al (1993) A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496–2502

    PubMed  CAS  Google Scholar 

  35. Bonilla MA, Dale D, Zeidler C et al (1994) Long-term safety of treatment with recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 88:723–730

    Article  PubMed  CAS  Google Scholar 

  36. Welte K, Zeidler C, Dale DC (2006) Severe congenital neutropenia. Semin Hematol 43:189–195

    Article  PubMed  CAS  Google Scholar 

  37. Zeidler C, Germeshausen M, Klein C, Welte K (2009) Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 144:459–467

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Hematopoiesis, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Karl Welte

Authors
  1. Karl Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Welte .

Editor information

Editors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, 91320, California, USA

    Graham Molineux

  2. MA Foote Associates, Par Five Court 4284, Westlake Village, 91362, California, USA

    MaryAnn Foote

  3. Amgen, Inc., One Amgen Center Dr. 1, Thousand Oaks, 91320, California, USA

    Tara Arvedson

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Welte, K. (2012). Discovery of G-CSF and Early Clinical Studies. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_2

Download citation

Publish with us

Policies and ethics

Search

Navigation